{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '88', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.1.7', 'Assignment of Treatment/Randomization Number', 'All eligible participants will be randomly allocated and will receive a', 'treatment/randomization number. The treatment/randomization number identifies the', 'participant for all procedures occurring after treatment allocation/randomization. Once a', 'treatment/randomization number is assigned to a participant, it can never be re-assigned to', 'another participant.', 'A single participant cannot be assigned more than 1 treatment/randomization number.', '8.1.8', 'Study Intervention Administration', 'Study intervention should begin within 3 days of randomization.', 'Study intervention will be administered by the investigator and/or study staff according to the', 'specifications within the Pharmacy Manual.', '8.1.8.1', 'Timing of Dose Administration', '8.1.8.1.1', 'Lenvatinib/Matching Placebo', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section is no longer applicable.', 'Lenvatinib/matching placebo 20 mg (two 10-mg capsules) QD will be taken orally with', 'water (with or without food) in 21-day cycles at approximately the same time each day. On', 'Day 1 of each pembrolizumab cycle, lenvatinib/matching placebo will be administered 0-4', 'hours after pembrolizumab.', 'If a lenvatinib/matching placebo dose is missed and cannot be taken within 12 hours, then', 'that dose should be skipped and the next dose should be taken at the usual time of', 'administration.', 'For nonvisit days, lenvatinib will be taken at home.', 'When a participant attends a study visit, he or she will bring any unused capsules.', '8.1.8.1.2', 'Pembrolizumab', 'Pembrolizumab will be administered as a 30-minute IV infusion on Day 1 of each 21-day', 'cycle. Sites should make every effort to target infusion timing to be as close to 30 minutes as', 'possible. However, given the variability of infusion pumps from site to site, a window of', '-5 minutes and +10 minutes is permitted (ie, infusion time is 30 minutes: -5 - min/+10 min).', 'After Cycle 1 Day 1, pembrolizumab may be administered up to 3 days before or after the', 'scheduled Day 1 of each subsequent cycle for administrative reasons.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '89', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Administration of pembrolizumab will be witnessed by the investigator and/or study staff.', 'The total volume of study treatment infused will be compared with the total volume prepared', 'to determine compliance with each dose administered.', '8.1.8.2', 'Lenvatinib Compliance', 'Lenvatinib compliance will be calculated by the Sponsor until discontinuation, based on the', 'drug accountability documented by the site staff and monitored by the Sponsor/designee. The', 'objective is 100% compliance, and investigators and their staff should evaluate compliance at', 'each visit and take appropriate steps to optimize compliance.', '8.1.9', 'Discontinuation and Withdrawal', 'Participants who discontinue study intervention prior to completion of the treatment period', 'should be encouraged to continue to be followed for all remaining study visits as outlined in', 'the SoA and Section 8.11.4.', 'When a participant withdraws from participation in the study, all applicable activities', 'scheduled for the final study visit should be performed (at the time of withdrawal). Any AEs', 'that are present at the time of withdrawal should be followed in accordance with the safety', 'requirements outlined in Section 8.4.3.', '8.1.10', 'Participant Blinding/Unblinding', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study and the study is unblinded. Participants who remain on treatment will', 'receive open-label pembrolizumab monotherapy as per protocol.', '8.1.11', 'Calibration of Equipment', 'The investigator or qualified designee has the responsibility to ensure that any device or', 'instrument used for a clinical evaluation/test during a clinical study that provides information', 'about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably', 'calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible.', 'Documentation of equipment calibration must be retained as source documentation at the', 'study site.', '8.2', 'Efficacy/Immunogenicity Assessments', '8.2.1', 'Tumor Scans and Assessment of Disease', 'NOTE: After amendment 007-06, imaging obtained on study will be submitted to the', 'imaging vendor but these will not be assessed; similarly, verification of PD is no longer', 'needed before treatment discontinuation. This section was updated accordingly.', 'Throughout this section, the term \"scan\" refers to any medical imaging data used to assess', 'tumor burden and may include cross-sectional imaging (such as CT or MRI), or other', 'methods as specified in this protocol.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}